Cagrilintide
Cagrilintide is a peptide, indexed here under Amylin and amylin receptor agonists.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Amylin and amylin receptor agonists |
| CAS registry number | 1415456-99-3[1] |
| PubChem CID | 171397054[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C194H312N54O59S2[1] |
| Molecular weight | 4409 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Cagrilintide is described in a 2021 Journal of Medicinal Chemistry paper as a long-acting amylin analogue, and a 2021 Journal of Pharmacology and Experimental Therapeutics paper reports AM833 as an agonist of calcitonin family G protein-coupled receptors, compared with six selective analogues. A 2025 EBioMedicine paper reports that it lowers bodyweight through brain amylin receptors 1 and 3 in its model, and a 2022 Biomedicine and Pharmacotherapy paper compares dual amylin and calcitonin receptor agonists.
The clinical records concern once-weekly administration, alone and with semaglutide. A 2021 Lancet paper reports a multicentre randomised trial of once-weekly cagrilintide for weight management, a 2021 Lancet paper reports safety, tolerability and pharmacokinetics of concomitant administration with semaglutide, a 2023 Lancet paper reports co-administration in type 2 diabetes, and two 2025 New England Journal of Medicine papers report the combination in adults with overweight or obesity, with and without type 2 diabetes.
[3, 4, 5, 6, 7, 8, 9, 10, 11]Reported mechanism
A long-acting amylin analogue reported in the retrieved records to act at amylin and calcitonin family receptors, with brain amylin receptors 1 and 3 named in a 2025 record.
[3, 5]Stated in the titles of the cited 2021 Journal of Medicinal Chemistry and 2025 EBioMedicine papers.
Targets named in the cited records: amylin receptors, calcitonin receptor family.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Cagrilintide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- AM833
- NNC0174-0833
Where this page sits
Research records
Cited research records for Cagrilintide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Side-by-side pages that include Cagrilintide
Compounds indexed next to it
- Pramlintide — Amylin and amylin receptor agonists
- Semaglutide — Incretin receptor agonists
- Amylin — Amylin and amylin receptor agonists
- Eloralintide — Amylin and amylin receptor agonists
- Petrelintide — Amylin and amylin receptor agonists
Class page: Amylin and amylin receptor agonists. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Cagrilintide?
Cagrilintide is described in a 2021 Journal of Medicinal Chemistry paper as a long-acting amylin analogue, and a 2021 Journal of Pharmacology and Experimental Therapeutics paper reports AM833 as an agonist of calcitonin family G protein-coupled receptors, compared with six selective analogues. A 2025 EBioMedicine paper reports that it lowers bodyweight through brain amylin receptors 1 and 3 in its model, and a 2022 Biomedicine and Pharmacotherapy paper compares dual amylin and calcitonin receptor agonists.
Which class is Cagrilintide indexed under?
Cagrilintide is indexed under Amylin and amylin receptor agonists. This class groups the pancreatic hormone amylin, also called islet amyloid polypeptide, and the synthetic analogues modelled on it.
What does the FDA application register show for Cagrilintide?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 171397054, Cagrilintide. PubChem, National Library of Medicine (2026). pubchem:171397054
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:cagrilintide
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
- AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of pharmacology and experimental therapeutics (2021). pmid:33727283
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022). pmid:36242844
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England) (2021). pmid:34798060
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet (London, England) (2021). pmid:33894838
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England) (2023). pmid:37364590
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine (2025). pmid:40544433
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine (2025). pmid:40544432
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.